Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Merck Gets EU Recommendations for Welireg Kidney Cancer Combo, Enflonsia RSV Expansion

Merck Gets EU Recommendations for Welireg Kidney Cancer Combo, Enflonsia RSV Expansion

MT newswireMT newswire2026/11/13 11:20
07:20 AM EST, 11/13/2026 (MT Newswires) -- Merck & Co (MRK) said Friday the European Medicines Agency's CHMP recommended approval of Welireg, or belzutifan, plus lenvatinib for adults with advanced renal cell carcinoma with a clear cell component following PD-1 or PD-L1 inhibitor treatment. The CHMP also recommended expanding Enflonsia's, or clesrovimab's, authorization to prevent RSV lower respiratory tract disease in children up to 24 months old at increased risk for severe RSV disease through their second RSV season. The Welireg recommendation is based on Phase 3 LITESPARK-011 results showing a 26% reduction in the risk of disease progression or death versus cabozantinib. Overall survival, the study's other dual primary endpoint, did not reach statistical significance, although the combination reduced the risk of death by 15%, Merck said. The combination also showed an objective response rate of 53.1%, compared with 40.2% for cabozantinib. The Enflonsia recommendation is supported by Phase 3 SMART trial results. Enflonsia is already approved in the European Union to prevent RSV lower respiratory tract disease in infants during their first RSV season. The European Commission is expected to make final decisions on both recommendations within two months, Merck said.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!